$CSTL
Castle Biosciences Inc Stock $cstl

$cstl Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000144736222000045 Filed on February 28, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$25.04M	$94.09M	$17.30M
YoY Change	44.74%	50.18%	-1.91%
Cost Of Revenue	$4.597M	$15.82M	$2.670M
YoY Change	72.17%	63.37%	32.84%
Gross Profit	$20.44M	$78.26M	$14.63M
YoY Change	39.76%	47.77%	-6.39%
Gross Profit Margin	81.64%	83.18%	84.55%
Selling, General & Admin	$24.94M	$86.74M	$14.93M
YoY Change	67.02%	80.21%	51.88%
% of Gross Profit	121.98%	110.83%	102.08%
Research & Development	$9.372M	$29.65M	$4.560M
YoY Change	105.53%	123.64%	44.3%
% of Gross Profit	45.85%	37.88%	31.18%
Depreciation & Amortization	$1.451M	$3.407M	$160.0K
YoY Change	806.88%	621.82%	60.0%
% of Gross Profit	7.1%	4.35%	1.09%
Operating Expenses	$35.61M	$116.4M	$17.66M
YoY Change	101.66%	89.59%	35.74%
Operating Profit	-$15.17M	-$40.08M	-$3.034M
YoY Change	400.03%	512.64%	-216.07%
Interest Expense	$16.00K	$1.000K	-$380.0K
YoY Change	-104.21%	-99.96%	-22.45%
% of Operating Profit
Other Income/Expense, Net			$0.00
YoY Change
Pretax Income	-$15.16M	-$40.01M	-$4.810M
YoY Change	215.07%	292.27%	-325.82%
Income Tax	-$8.725M	-$8.720M	$80.00K
% Of Pretax Income
Net Earnings	-$6.430M	-$31.29M	-$4.889M
YoY Change	31.52%	204.28%	-337.91%
Net Earnings / Revenue	-25.68%	-33.26%	-28.26%
Basic Earnings Per Share		-$1.24	-$0.23
Diluted Earnings Per Share	-$253.8K	-$1.24	-$0.23
COMMON SHARES
Basic Shares Outstanding	25.30M shares	25.14M shares	19.91M shares
Diluted Shares Outstanding		25.14M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$329.6M	$329.6M	$409.9M
YoY Change	-19.58%	-19.58%	314.88%
Cash & Equivalents	$329.6M	$329.6M	$409.9M
Short-Term Investments	$0.00
Other Short-Term Assets	$4.807M	$4.807M	$4.800M
YoY Change	0.15%	0.15%	140.0%
Inventory	$2.021M	$2.021M	$2.217M
Prepaid Expenses
Receivables	$17.28M	$17.28M	$12.76M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$353.7M	$353.7M	$429.6M
YoY Change	-17.66%	-17.66%	268.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.501M	$16.88M	$7.102M
YoY Change	33.78%	137.8%	244.76%
Goodwill	$0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.715M	$1.715M	$1.536M
YoY Change	11.65%	14.33%	1037.78%
Total Long-Term Assets	$108.8M	$108.8M	$9.734M
YoY Change	1018.03%	1021.95%	217.59%
TOTAL ASSETS
Total Short-Term Assets	$353.7M	$353.7M	$429.6M
Total Long-Term Assets	$108.8M	$108.8M	$9.734M
Total Assets	$462.6M	$462.6M	$439.3M
YoY Change	5.29%	5.3%	266.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.546M	$2.546M	$2.098M
YoY Change	21.35%	21.24%	12.49%
Accrued Expenses	$20.58M	$20.58M	$12.10M
YoY Change	70.08%	70.08%	61.33%
Deferred Revenue	$0.00		$6.615M
YoY Change	-100.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$105.0K	$105.0K	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$24.89M	$24.89M	$20.88M
YoY Change	19.21%	19.07%	36.54%
LONG-TERM LIABILITIES
Long-Term Debt	$124.0K	$124.0K	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$124.0K	$25.19M	$1.026M
YoY Change	-87.91%	799.54%	926.0%
Total Long-Term Liabilities	$124.0K	$25.31M	$1.026M
YoY Change	-87.91%	803.96%	-94.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.89M	$24.89M	$20.88M
Total Long-Term Liabilities	$124.0K	$25.31M	$1.026M
Total Liabilities	$50.83M	$50.83M	$23.64M
YoY Change	115.05%	115.39%	-31.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$93.77M		-$62.50M
YoY Change	50.04%		19.7%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$411.7M	$411.7M	$415.7M
YoY Change
Total Liabilities & Shareholders Equity	$462.6M	$462.6M	$439.3M
YoY Change	5.29%	5.3%	266.88%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$6.430M	-$31.29M	-$4.889M
YoY Change	31.52%	204.28%	-337.91%
Depreciation, Depletion And Amortization	$1.451M	$3.407M	$160.0K
YoY Change	806.88%	621.82%	60.0%
Cash From Operating Activities	-$2.781M	-$18.98M	-$430.0K
YoY Change	546.74%	-292.43%	-109.56%
INVESTING ACTIVITIES
Capital Expenditures	-$893.0K	$3.483M	-$590.0K
YoY Change	51.36%	-26.69%	68.57%
Acquisitions		$0.00
YoY Change
Other Investing Activities	-$30.00M	-$63.17M	$0.00
YoY Change
Cash From Investing Activities	-$30.89M	-$66.66M	-$590.0K
YoY Change	5135.42%	1303.9%	68.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	126.0K	$5.421M	227.8M
YoY Change	-99.94%	-98.23%	98952.17%
NET CHANGE
Cash From Operating Activities	-2.781M	-$18.98M	-430.0K
Cash From Investing Activities	-30.89M	-$66.66M	-590.0K
Cash From Financing Activities	126.0K	$5.421M	227.8M
Net Change In Cash	-33.54M	-$80.22M	226.8M
YoY Change	-114.79%	-125.79%	5078.08%
FREE CASH FLOW
Cash From Operating Activities	-$2.781M	-$18.98M	-$430.0K
Capital Expenditures	-$893.0K	$3.483M	-$590.0K
Free Cash Flow	-$1.888M	-$22.47M	$160.0K
YoY Change	-1280.0%	-539.3%	-96.7%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001447362
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2020	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-38984
CY2021	dei	Entity Registrant Name EntityRegistrantName	CASTLE BIOSCIENCES, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0701774
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	505 S. Friendswood Drive
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 401
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Friendswood
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77546
CY2021	dei	City Area Code CityAreaCode	866
CY2021	dei	Local Phone Number LocalPhoneNumber	788-9007
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2021	dei	Trading Symbol TradingSymbol	CSTL
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4807000	USD
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	1500000000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25410602	shares
CY2021	dei	Auditor Name AuditorName	KPMG LLP
CY2021	dei	Auditor Location AuditorLocation	San Diego, CA
CY2021	dei	Auditor Firm AuditorFirmId	185
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	329633000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	409852000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17282000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12759000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	2021000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	2217000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4766000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	353743000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	429594000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	1308000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	1096000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	9501000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	7102000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7383000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7383000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	88922000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1715000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1536000	USD
CY2021Q4	us-gaap	Assets Assets	462572000	USD
CY2020Q4	us-gaap	Assets Assets	439328000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2546000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2098000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15483000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9108000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6615000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1179000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5678000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3055000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	24886000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20876000	USD
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	18287000	USD
CY2020Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6900000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1735000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	635000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	124000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1026000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	50832000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	23637000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2020Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25378520	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25378520	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24812487	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24812487	shares
CY2021Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	25000	USD
CY2020Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	25000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	505482000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	478162000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93767000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62496000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	411740000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	415691000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	462572000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	439328000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	94085000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	62649000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15822000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9685000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29646000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13256000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	86738000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	48132000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1958000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	0	USD
CY2020	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1882000	USD
CY2021	cstl	Operating Expenses Net Of Other Operating Income OperatingExpensesNetOfOtherOperatingIncome	134164000	USD
CY2020	cstl	Operating Expenses Net Of Other Operating Income OperatingExpensesNetOfOtherOperatingIncome	69191000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-40079000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-6542000	USD
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	68000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	373000	USD
CY2021	us-gaap	Interest Expense InterestExpense	1000	USD
CY2020	us-gaap	Interest Expense InterestExpense	2634000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1397000	USD
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-40012000	USD
CY2020	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-10200000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8720000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	84000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-31292000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31292000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-10284000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10284000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.24
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.24
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25137000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18929000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25137000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18929000	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	85113000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	8309000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1593000	USD
CY2020	cstl	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	0	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	329664000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1296000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-10284000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	415691000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	21740000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4234000	USD
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-781000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	39000	USD
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2088000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-31292000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	411740000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-31292000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-10284000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3407000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	472000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	21740000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	8309000	USD
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	839000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-8736000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1397000	USD
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	16000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4631000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1663000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-617000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2815000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-327000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	980000	USD
CY2021	cstl	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-931000	USD
CY2020	cstl	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	0	USD
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	180000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1401000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-182000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	169000	USD
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-852000	USD
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	6208000	USD
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	3329000	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-8350000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	8350000	USD
CY2021	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	2286000	USD
CY2020	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	561000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-276000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	272000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18983000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	9865000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3483000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4751000	USD
CY2021	cstl	Payments To Acquire Asset Acquisitions Net Of Cash Acquired PaymentsToAcquireAssetAcquisitionsNetOfCashAcquired	63184000	USD
CY2020	cstl	Payments To Acquire Asset Acquisitions Net Of Cash Acquired PaymentsToAcquireAssetAcquisitionsNetOfCashAcquired	0	USD
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	10000	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-66657000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4748000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	330041000	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	336000	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2021	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	USD
CY2020	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	27359000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4234000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1593000	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	781000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2312000	USD
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1615000	USD
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	8000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5421000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	305890000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-80219000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	311007000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	409852000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98845000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	329633000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	409852000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1978000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	16000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	102000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	33000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	58000	USD
CY2021	cstl	Property And Equipment Acquired With Tenant Improvement Allowance PropertyAndEquipmentAcquiredWithTenantImprovementAllowance	54000	USD
CY2020	cstl	Property And Equipment Acquired With Tenant Improvement Allowance PropertyAndEquipmentAcquiredWithTenantImprovementAllowance	714000	USD
CY2021Q4	cstl	Asset Acquisition Post Closing Purchase Price Adjustment Receivable AssetAcquisitionPostClosingPurchasePriceAdjustmentReceivable	519000	USD
CY2020Q4	cstl	Asset Acquisition Post Closing Purchase Price Adjustment Receivable AssetAcquisitionPostClosingPurchasePriceAdjustmentReceivable	0	USD
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	18287000	USD
CY2020Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	0	USD
CY2021	cstl	Offering Costs Incurred But Not Yet Paid OfferingCostsIncurredButNotYetPaid	0	USD
CY2020	cstl	Offering Costs Incurred But Not Yet Paid OfferingCostsIncurredButNotYetPaid	377000	USD
CY2021	cstl	Exercise Of Common Stock Warrants Noncash ExerciseOfCommonStockWarrantsNoncash	0	USD
CY2020	cstl	Exercise Of Common Stock Warrants Noncash ExerciseOfCommonStockWarrantsNoncash	250000	USD
CY2020Q2	cstl	Centers For Medicare And Medicaid Services Accelerated And Advanced Payment Program Payment Received CentersForMedicareAndMedicaidServicesAcceleratedAndAdvancedPaymentProgramPaymentReceived	8300000	USD
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	Certain prior year amounts in our consolidated statements of operations and comprehensive loss have been reclassified to conform to the current year presentation. Specifically, we no longer present gross margin on our statements of operations and comprehensive loss and therefore the cost of sales line is now presented within the operating expenses section. This reclassification had no impact on operating loss, loss before income taxes, net loss, comprehensive loss or loss per share.
CY2021	us-gaap	Use Of Estimates UseOfEstimates	The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include revenue recognition, the valuation of stock-based compensation, assessing future tax exposure and the realization of deferred tax assets, the useful lives and recoverability of long-lived assets, the valuation of acquired intangible assets, the valuation of contingent consideration and other contingent liabilities. We base these estimates on historical and anticipated results, trends, and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. We have considered the potential impact of the COVID-19 pandemic on our estimates and assumptions. The extent to which the COVID-19 pandemic may impact our estimates in future periods is uncertain and subject to change.
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Cash deposits at financial institutions may exceed the amount of insurance provided by the FDIC. Management believes that we are not exposed to significant credit risk on our cash deposits due to the financial position of the institutions in which deposits are held. We have not experienced any losses on our cash or cash equivalents.
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2020Q2	cstl	Other Operating Income Loss Cares Act OtherOperatingIncomeLossCARESAct	1900000	USD
CY2021Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	12071000	USD
CY2020Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	7175000	USD
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	2036000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	789000	USD
CY2020Q4	cstl	Deferred Payroll Taxes Cares Act DeferredPayrollTaxesCARESAct	551000	USD
CY2021Q4	cstl	Deferred Payroll Taxes Cares Act DeferredPayrollTaxesCARESAct	276000	USD
CY2021	cstl	Contract With Customer Customer Payment Terms ContractWithCustomerCustomerPaymentTerms	P30D
CY2021	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	3324000	USD
CY2020	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	176000	USD
CY2021	cstl	Revenue From Contract With Customer Revenue Not Yet Recognized Number Of Claims In Adjudication Process RevenueFromContractWithCustomerRevenueNotYetRecognizedNumberOfClaimsInAdjudicationProcess	2698	claim
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	94085000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	62649000	USD
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3521000	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2924000	shares
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	18287000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	12543000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	8756000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	3042000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	1654000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	9501000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	7102000	USD
CY2021	us-gaap	Depreciation Depreciation	1448000	USD
CY2020	us-gaap	Depreciation Depreciation	472000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	90880000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1958000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	88922000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	6681000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	6681000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	6700000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	6681000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	6672000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2000000.0	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	55507000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	88922000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1905000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1543000	USD
CY2021Q4	cstl	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	1655000	USD
CY2020Q4	cstl	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	348000	USD
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	760000	USD
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	536000	USD
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	695000	USD
CY2020Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	276000	USD
CY2021Q4	cstl	Accrued Payor Refunds Current AccruedPayorRefundsCurrent	386000	USD
CY2020Q4	cstl	Accrued Payor Refunds Current AccruedPayorRefundsCurrent	0	USD
CY2021Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	277000	USD
CY2020Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	352000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5678000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3055000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7383000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	229000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1179000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	105000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6900000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	124000	USD
CY2020	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	548000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1450000	USD
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	8000	USD
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000	USD
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	29000	USD
CY2021	us-gaap	Lease Cost LeaseCost	1488000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	187000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1145000	USD
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1000	USD
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	8000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2900000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y1M6D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.049
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.050
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1258000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	108000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1287000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	108000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1302000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	26000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1218000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	689000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	4609000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	10363000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	242000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2284000	USD
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	13000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8079000	USD
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	229000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1164000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1148000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1142000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1154000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1119000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1037000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	6764000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	USD
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	18287000	USD
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	0	USD
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	18287000	USD
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0
CY2021	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0
CY2020	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2021	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2637966	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.30
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1286065	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	49.63
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	460207	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.53
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	94322	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	27.51
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3369502	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28.11
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	841336	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	48.97
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	414890	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.13
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	209260	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	33.97
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3586688	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	34.75
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	45970000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1332487	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	23.31
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y6M
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	28845000	USD
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	10255	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.39
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21740000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8309000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	99251000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y3M18D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	27191000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	18377000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2021	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	16000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	84000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	16000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	84000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-8726000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-10000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-8736000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8720000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	84000	USD
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-157000	USD
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-40012000	USD
CY2020	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-10200000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-8402000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2142000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1764000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-311000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	0	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	235000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1658000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	703000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2570000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2784000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-880000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-781000	USD
CY2021	cstl	Effective Income Tax Rate Reconciliation Nondeductible Expense Officers Compensation Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount	1571000	USD
CY2020	cstl	Effective Income Tax Rate Reconciliation Nondeductible Expense Officers Compensation Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensationAmount	963000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	39000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8720000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	84000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	24316000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13720000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	4168000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2730000	USD
CY2021Q4	cstl	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	2114000	USD
CY2020Q4	cstl	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	46000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2202000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	761000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3670000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1777000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	240000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	2285000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	776000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	36710000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	19034000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17774000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15204000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	18936000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3830000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	330000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	289000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	12913000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	0	USD
CY2021Q4	cstl	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	2166000	USD
CY2020Q4	cstl	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	0	USD
CY2021Q4	cstl	Deferred Tax Liabilities Change In Accounting Method DeferredTaxLiabilitiesChangeInAccountingMethod	1877000	USD
CY2020Q4	cstl	Deferred Tax Liabilities Change In Accounting Method DeferredTaxLiabilitiesChangeInAccountingMethod	2765000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	19571000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3830000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	635000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2021Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	3670000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-8726000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17774000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15204000	USD

Files In Submission

Name	View Source	Status
0001447362-22-000045-index-headers.html	Edgar Link	pending
0001447362-22-000045-index.html	Edgar Link	pending
0001447362-22-000045.txt	Edgar Link	pending
0001447362-22-000045-xbrl.zip	Edgar Link	pending
cstl-20211231.htm	Edgar Link	pending
cstl-20211231.xsd	Edgar Link	pending
cstl-20211231_cal.xml	Edgar Link	unprocessable
cstl-20211231_def.xml	Edgar Link	unprocessable
cstl-20211231_g1.jpg	Edgar Link	pending
cstl-20211231_g10.jpg	Edgar Link	pending
cstl-20211231_g11.jpg	Edgar Link	pending
cstl-20211231_g12.jpg	Edgar Link	pending
cstl-20211231_g13.jpg	Edgar Link	pending
cstl-20211231_g14.jpg	Edgar Link	pending
cstl-20211231_g15.jpg	Edgar Link	pending
cstl-20211231_g16.jpg	Edgar Link	pending
cstl-20211231_g17.jpg	Edgar Link	pending
cstl-20211231_g18.jpg	Edgar Link	pending
cstl-20211231_g19.jpg	Edgar Link	pending
cstl-20211231_g2.jpg	Edgar Link	pending
cstl-20211231_g3.jpg	Edgar Link	pending
cstl-20211231_g4.jpg	Edgar Link	pending
cstl-20211231_g5.jpg	Edgar Link	pending
cstl-20211231_g6.jpg	Edgar Link	pending
cstl-20211231_g7.jpg	Edgar Link	pending
cstl-20211231_g8.jpg	Edgar Link	pending
cstl-20211231_g9.jpg	Edgar Link	pending
cstl-20211231_htm.xml	Edgar Link	completed
cstl-20211231_lab.xml	Edgar Link	unprocessable
cstl-20211231_pre.xml	Edgar Link	unprocessable
exhibit1011non-employeedir.htm	Edgar Link	pending
exhibit211subsidiaries.htm	Edgar Link	pending
exhibit23consent10-k2021.htm	Edgar Link	pending
exhibit311yearend2021.htm	Edgar Link	pending
exhibit312yearend2021.htm	Edgar Link	pending
exhibit321yearend2021.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CSTL
Castle Biosciences Inc Stock $cstl

2021 Q4 Form 10-K Financial Statement

#000144736222000045 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSTL Castle Biosciences Inc Stock $cstl

2021 Q4 Form 10-K Financial Statement

#000144736222000045 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSTL
Castle Biosciences Inc Stock $cstl